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Gains in medication affordability following Medicare Part D 
are eroding among elderly with multiple chronic conditions 
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Abstract 
Elderly Americans, especially those with multiple chronic 
conditions, face difficulties paying for prescriptions, 
resulting in worse adherence and discontinuation of therapy 
(“cost-related medication nonadherence” or CRN). We investigated 
whether the gains in medication affordability attributable to 
Medicare Part D implementation in January 2006 persisted during 
the six years that followed. Overall, we found continued 
incremental improvements in medication affordability in the 
early years of Part D (2007-2009), which then eroded during more 
recent years (2009-2011). Among elderly beneficiaries with four 
or more chronic conditions, we observed an increase in the 
prevalence of CRN from 14.4% in 2009 to 17.0% in 2011, reversing 
previous downward trends. Similarly, the prevalence of forgoing 
basic needs in order to purchase medicines among the sickest 
elderly decreased from 8.7% in 2007 to 6.8% in 2009, then rose 
to 10.2% in 2011. Our findings highlight the need for targeted 
policy efforts to alleviate the persistent burden of drug 
treatment costs in this vulnerable population.   
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Introduction 
 Elderly Americans typically have few financial resources 
available for prescription drugs.1 High out-of-pocket drug costs 
are associated with worse adherence and medication 
discontinuation.2 Such cost-related medication nonadherence (CRN) 
can lead to adverse health outcomes including worse health 
status and increased risk of hospitalization.3-5  
 Adequate adherence to medications is particularly important 
for seniors with multiple chronic conditions. Effective and 
efficient care for a growing elderly population with multiple 
chronic conditions is among the most important challenges the US 
health care system faces.6 Yet, older individuals with multiple 
chronic conditions are at especially high risk of CRN due to 
intensive medication use and high out-of-pocket costs.7  
 The Medicare Part D drug benefit was implemented in 2006 to 
increase economic access to medicines by decreasing 
beneficiaries’ out-of-pocket drug expenditures.8 Early 
evaluations of Part D indicated modest but significant 
nationwide reductions in CRN and forgoing basic needs to pay for 
medicines in 2006,9 which were sustained in 2007.10 Improvements 
in ability to afford medicines were not consistent across 
subgroups.9-11 In particular, improvements in CRN among elderly 
with four or more chronic conditions lagged behind improvements 
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for healthier beneficiaries.9 Nevertheless, Part D resulted in 
significant increases in prescription drug use and lower out-of-
pocket drug costs among almost all subgroups of the Medicare 
population.12  
 In 2008, the US entered the worst economic recession since 
the Great Depression. Between 2007 and 2010, the housing market 
collapsed, financial markets sank into turmoil, and family 
incomes, home prices, and investment portfolio values fell;13 
wealth for elderly households declined by approximately 20% 
between 2007 and 2009.14, 15 The recession and its aftermath left 
many elderly Americans facing unprecedented economic 
uncertainty.16 In addition, over the years following Part D 
implementation, changes in Part D plan benefits potentially 
introduced barriers to drug therapy and shifted costs onto 
patients.17, 18  
 There have been no published reports on the prevalence of 
CRN among the multimorbid elderly in Medicare since 2008.10, 19 In 
this study, we evaluate recent national trends in CRN and 
spending less on basic needs to afford medicines among elderly 
beneficiaries by illness burden, and explore the extent to which 
improvements in affordable access to medications resulting from 
Part D persisted during subsequent years. 
5 
 
Methods 
Data Source and Sample 
 We used the Access-to-Care (ATC) files of the Medicare 
Current Beneficiary Survey (MCBS), the principal national survey 
for Medicare beneficiaries. Administered by the Centers for 
Medicare and Medicaid Services (CMS), the MCBS is a 
longitudinal, nationally representative rotating panel survey of 
approximately 16,000 disabled and elderly Medicare enrollees, 
who are representative of 42.5 million beneficiaries nationwide. 
Respondents provide information on health care utilization, 
expenditures and sources of payments, health insurance coverage, 
health status and functioning, and a variety of demographic and 
behavioral factors.20  
 The MCBS ATC files used in this study included the annual 
“always enrolled” beneficiary population, i.e., excluding 
individuals who newly enrolled in Medicare or died during a 
given calendar year. ATC data primarily consist of responses to 
the main fall interview, following a four-year panel survey 
design. The annual replenishment strategy replaces those who 
have completed survey participation, died, or been lost to 
follow-up, ensuring a representative sample in each calendar 
year. The average response rate across the study years (2006-
2011) was 79.7% among first-time respondents and 67.0% among all 
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respondents. We included all community-dwelling elderly 
respondents (approximately 79% of the total, excluding persons 
under 65 years and those residing in long-term care facilities) 
from 2006 through 2011 (n = 70,067 person-years). Accounting for 
overlapping samples among years, the total number of individual 
respondents was 31,713.  
Outcome Measures 
 Since 2004, the MCBS fall interview has included a set of 
questions on the affordability of medications which were 
developed in collaboration with CMS, tested for reliability,21 
and used in several studies by the research team.7, 9-11, 21, 22 The 
main outcomes for this study were cost-related medication 
nonadherence (hereafter referred to as CRN) and spending less on 
other basic needs to afford medicines (forgoing basic needs).21, 
23, 24 We used our validated binary composite measure of CRN if a 
respondent answered yes/ever during the current year to any of 
the following questions: “did not fill a prescription because of 
cost?”; “skipped doses to make the medicine last longer?”; 
“taken smaller doses of a medicine to make the medicine last 
longer?”; “delayed filling prescription because of cost?”; or, 
“any medicines prescribed for you that you did not get?” in 
combination with “reason you did not obtain the medicine was you 
thought it would cost too much”. We also examined a separate 
7 
 
binary measure of having spent less money on food, heat, or 
other basic needs in order to have money for medicine.7, 9-11 
Statistical Analysis 
 We estimated the rates and 95% confidence intervals (CIs) 
of demographic and health characteristics of respondents. 
Covariates included previously validated predictors of CRN:7, 25 
age and sex, in addition to self-reported income, race, health 
status,26 and presence of specific diseases or conditions. 
Morbidities included cardiac disease, hypertension, diabetes, 
cancer, stroke, arthritis, dementia, psychiatric disorder 
(including depression), neurological disorder (excluding 
stroke), and pulmonary illness (including asthma and chronic 
obstructive pulmonary disease). We then calculated the 
unadjusted annual prevalence of CRN and spending less on basic 
needs with 95% CIs for all study years (2006-2011), as well as 
for 2004 and 2005 to illustrate pre-Part D levels. All survey 
analyses were weighted to represent the national population of 
community-dwelling elderly Medicare beneficiaries, using the 
annual cross-sectional survey weights provided in the MCBS.27  
 To model changes in CRN and spending less on basic needs in 
the years since Part D implementation, we used logistic 
regression models. Dividing the study years into two periods, 
our models compared the odds of CRN and spending less on basic 
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needs between pairs of years (2009 vs. 2007, and 2011 vs. 2009), 
as well as the entire period (2011 vs. 2007). The year 2007 was 
the first for which the Part D benefit was fully implemented; 
2009 was the first year following the financial market collapse 
in September 2008, which triggered public awareness of the 
economic crisis and steep declines in multiple indicators, 
including the unemployment rate, family income and wealth, and 
housing prices.28-30 During our final study period (2009 to 2011), 
external data suggest that scattered signs of economic recovery 
did not often translate into improved conditions for the 
elderly; rather, most indicators such as income and savings 
showed continued stagnation.16, 31-33  
 As in previous reports,9, 10 our models controlled for 
interview sequence, demographic characteristics (sex, age, 
income, and race), and health status (number of morbidities and 
health status). We repeated these analyses separately for eight 
subgroups based on the number of chronic conditions (0-3 and 
≥4), income (<$25 000 and ≥$25 000), and type of prescription 
drug coverage (Part D low-income subsidy, Medicare Advantage, 
stand-alone prescription drug plan, and non-Part D).7, 25 All 
analyses were conducted in STATA version 12 (StataCorp LP, 
College Station, TX). This study was reviewed and approved by 
the Human Subjects Committee of the Harvard Pilgrim Health Care 
Institute.
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Results 
Characteristics of Elderly Medicare Beneficiaries 
 The demographic and health characteristics of the 
community-dwelling elderly Medicare beneficiary population were 
similar across study years (Exhibit 1). The proportion reporting 
four or more conditions increased from 26.7% in 2007 to 27.6% in 
2011. During the same period, the proportion enrolled in 
Medicare Part D increased, particularly for Medicare Advantage 
plans (20.1% to 25.3%), while non-Part D drug coverage plans 
became less common.  
Unadjusted Changes in Medication Affordability 
 An estimated 14.9% of elderly beneficiaries experienced CRN 
in 2005, and 11.3% in 2007 after the full implementation of 
Medicare Part D (Supplementary Appendix Exhibit 1). Following a 
downward trend until 2009, when 10.2% of beneficiaries had CRN, 
the estimated prevalence of CRN subsequently increased to 10.8% 
in 2011. Similarly, the percentage of beneficiaries forgoing 
other needs to pay for medicines declined after Part D (8.8% in 
2005 to 5.6% in 2007), reaching 4.0% in 2009. In 2011, 5.3% of 
elderly beneficiaries cut back on basic needs to afford 
medications. 
 Between 2007 and 2011, elderly beneficiaries with non-Part 
D prescription drug coverage had consistently lower rates of CRN 
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and spending less on basic needs than those participating in 
Medicare Part D (Exhibit 2). The risk of foregoing basic needs 
to afford medications among beneficiaries receiving the low-
income subsidy was higher than that among other coverage groups. 
We observed similar increases in both measures across all major 
prescription drug coverage categories between 2009 and 2011.  
Changes in Medication Affordability by Morbidity Burden 
 Across all study years, elderly with multiple chronic 
conditions had more problems affording their medications than 
other elderly (Exhibit 3). In 2005, prior to Part D, an 
estimated 20.3% of elderly beneficiaries with four or more 
chronic conditions experienced CRN. In the early years following 
the initial Part D impact,9 both measures of economic barriers to 
paying for medicines continued to decline slightly: the 
prevalence of CRN decreased from 15.1% in 2007, after Part D, to 
14.4% in 2009. However, this trend reversed in subsequent years, 
rising to 17.0% in 2011. Similarly, the percentage of sicker 
beneficiaries forgoing other needs to pay for medicines declined 
after Part D implementation (12.3% in 2005 to 8.7% in 2007). 
These declines subsequently continued under Part D until the 
outcome reached its lowest point in 2009 (6.8%). However, by 
2011, the prevalence of forgoing basic needs had risen again to 
10.2% of sicker beneficiaries.  
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 Among elderly beneficiaries with three or fewer chronic 
conditions, prevalence of CRN also declined sharply following 
Medicare Part D implementation (from 15.7% in 2005 to 9.9% in 
2007), and continued declining until 2009, leveling off in 
subsequent years. The prevalence of spending less on basic needs 
declined from 7.6% in 2005 to 4.5% in 2007 and 2.9% in 2009, 
rising slightly to 3.5% in 2011.  
Adjusted Changes in Medication Affordability 
 Exhibit 4 shows the changes in CRN and spending less on 
basic needs over time estimated using multivariate models. The 
direction of change between 2007 and 2009 for both outcomes was 
consistently downward for all groups. Then, between 2009 and 
2011, the prevalence of affordability problems remained fairly 
stable among elderly beneficiaries with three or fewer chronic 
conditions, while the sickest elderly experienced pronounced 
increases. The odds of CRN among elderly beneficiaries with four 
or more conditions increased significantly by 20% between 2009 
and 2011 (OR: 1.20, 95% CI: 1.03, 1.40) (Supplemental Appendix 
Exhibit 2). Similarly, we detected a significant increase in the 
odds of forgoing basic needs in order to purchase medicines 
between 2009 and 2011 (OR: 1.54, 95% CI: 1.30, 1.82), reversing 
the previous downward trends (OR 2009 vs. 2007: 0.81, 95% CI: 
0.67, 0.99).   
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 An examination of the full 6-year period of observation 
confirms that early gains were reversed among the sickest 
beneficiaries. Elderly beneficiaries with four or more chronic 
conditions had significantly worse outcomes in 2011 compared to 
2007 (CRN OR: 1.18, 95% CI: 1.02, 1.36; forgoing basic needs OR: 
1.25, 95% CI: 1.04, 1.51). We also observed that the prevalence 
of foregoing basic needs to afford medications among the sickest 
elderly in 2011 was no longer significantly better than the 
level reported in 2005, prior to Part D implementation (OR 2011 
vs. 2005: 0.86, 95% CI: 0.72, 1.04). By contrast, there was no 
reversal among the healthier group. Those with fewer conditions 
had significantly better outcomes in 2011 as compared to 2007, 
though their improvements appeared to occur mainly between 2007 
and 2009. 
 We did not detect any significant changes in either measure 
when comparing 2007 to 2011 in subgroup analyses (Exhibit 4; 
Supplemental Appendix Exhibit 3). 
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Discussion 
 In this study, we investigated recent national trends in 
CRN and forgoing other basic needs to pay for medicines among 
elderly Medicare beneficiaries. Strikingly, we found that 
financial barriers to prescription drug therapy represent a 
continuing problem for the sickest Medicare beneficiaries, who 
are at higher risk of CRN due to illness burden, intense 
medication needs, and high out-of-pocket costs.7 For the first 
time since 2004, when affordability indicators were added to a 
nationally representative survey of elderly Medicare 
beneficiaries, a trajectory of improvements in both CRN and 
forgoing basic needs reversed course around 2009: drug 
affordability deteriorated significantly in subsequent years 
among the sickest elderly. In 2011, elderly individuals with 
four or more chronic conditions were worse off in terms of 
both outcomes than they had been in 2007. In fact, the risk of 
foregoing basic needs among this key group in 2011 was not 
significantly better than it had been prior to Part D, 
suggesting that both the original Part D impact and interim 
improvements may have been eliminated.  
 Several factors likely reversed the early gains in 
medication affordability following Part D implementation, and 
disproportionately affected the sickest elderly. The severe 
 14 
economic downturn in the US shrank incomes, asset values, and 
wealth for all age groups including the elderly. Elders also 
had high rates of mortgage delinquency, which has been 
associated with CRN.44 It is very likely that new economic 
strains affected the ability of elderly beneficiaries with 
multiple chronic conditions to afford their medications. 
During the same period, the zero cost-of-living adjustment 
(COLA) in social security may have also affected medication 
affordability.45 
 In addition, there is evidence of reduced drug coverage 
generosity among Part D plans in recent years.18 Over our 
observation period, more Part D plans have begun to charge 
deductibles and adopted tiered formularies. Plans have also 
generally increased patient copayments within tiers, reduced 
the proportion of medications covered by their formularies, 
and more frequently applied restrictions such as prior 
authorization requirements.17, 48 While these benefit changes 
may have been designed to steer patients toward less expensive 
medications, they may also have had the effect of introducing 
barriers to drug therapy and shifting the overall drug cost 
burden toward patients, particularly those with multiple 
chronic conditions.  
 We investigated whether the recent worsening trends in 
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medication affordability could be attributed to changes in 
beneficiaries’ type of prescription drug coverage, and found 
that there were similar increases across all major coverage 
sources. It is therefore unlikely that Part D plan changes 
alone were responsible for rising problems of access to 
medications.  Indeed, published reports documented similar 
reductions in generosity more generally in US health 
insurance, which potentially compounded the effect of the 
economic downturn.49, 50 Such changes across the healthcare 
system could explain why elderly Americans are reporting 
persistent affordability problems while news reports 
simultaneously exclaim that “[total US] spending on 
prescription drugs fell for the first time on record”.51 
 We found that beneficiaries who participated in the Part 
D program had a higher risk of CRN than other beneficiaries. 
The Affordable Care Act (ACA) has begun to broaden access to 
public and private health insurance and improve Medicare Part 
D coverage. Specifically, by 2020, CMS will gradually phase 
out the Medicare Part D coverage gap (or “doughnut hole”) in 
which beneficiaries who have reached a defined total drug 
spending threshold must then pay 100% out of pocket until they 
reach a “catastrophic” level.  
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Given the constant evolution of policies affecting the 
Medicare population, policymakers and researchers must closely 
monitor trends in affordability such as those we highlight 
here, and support more in-depth investigation of the 
underlying causes. Policymakers should also consider 
additional strategies to help the sickest beneficiaries, who 
clearly remain burdened by medication costs. Policy options 
include increased outreach to and participation in the Part D 
low-income subsidy for qualified individuals in need.55 
Beneficiaries may also need more assistance in selecting a 
Part D plan that fits their medical and financial 
circumstances, given reports that they often choose plans that 
require more out-of-pocket spending than necessary.57 Programs 
focusing on clinicians and pharmacists can help patients 
mitigate excessive costs, for example, by substituting lower-
cost therapies with comparable benefit-harm profiles.56 
Increasing low-income subsidy enrollment and assisting 
beneficiaries with better choices can potentially improve 
affordability for Medicare beneficiaries in all current 
coverage categories.  
 The findings of this study should be interpreted in light 
of its limitations. We are able to describe recent reversals 
in affordability, but the data do not permit us to 
definitively determine the root causes. For example, data on 
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actual drug utilization and out-of-pocket spending by MCBS 
respondents are not yet available for the most recent years of 
observation, and the recession literature does not clearly 
pinpoint the timing of harms as they affected specific 
population segments, such as the elderly. In addition, self-
reports could be subject to reporting and recall biases. 
Nevertheless, the affordability measures used in our study 
have been validated21, 23, 24 and used extensively in previous 
studies,7, 9-11, 22, 58 and we expect potential misreporting of CRN 
behavior to be consistent over time. 
 Perhaps unsurprisingly, we detected more statistically 
significant changes in our measure of cutting back on basic 
needs to afford medications, as compared to the CRN measure. 
This suggests that the basic needs question may be a more 
direct measure of patients’ economic hardship and more 
sensitive to changes in financial circumstances over time. CRN 
addresses specific clinical behaviors that are subject to 
influences beyond economic hardship, such as ongoing health 
system efforts to increase adherence and providers’ ability to 
adapt regimens to patients’ economic circumstances. In tandem, 
these measures have demonstrated their sensitivity and utility 
as a barometer of medication affordability in a stable survey 
population.  
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 The body of research evaluating the impact of Medicare 
Part D provided unequivocal evidence of population-level 
decreases in out-of-pocket costs and increased medication use 
following its implementation in 2006.12, 59 Nevertheless, using 
data on a nationally representative sample of Medicare 
beneficiaries, we provide updated evidence that many elderly 
Americans face persistent, and indeed, worsening, economic 
barriers to prescription drug therapy. Our finding that the 
gains in medication affordability among elderly with multiple 
chronic conditions following Part D were later lost during a 
period of both economic downturn and benefit changes 
highlights a pressing need to find new ways to ensure economic 
access to drug treatment for vulnerable Medicare 
beneficiaries.   
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Exhibit 1 – Characteristics of community-dwelling elderly Medicare 
beneficiaries in 2007, 2009, and 2011. 
 
% 
 
Characteristics 
2007 
(n = 12,190) 
2009 
(n = 11,393) 
2011 
(n = 11,600) 
Female sex 56.4 56.1 56.3 
Age groups    
65-74 50.8 52.2 53.0 
75-84 36.5 34.3 33.3 
≥85 12.7 13.5 13.6 
Income, <$25,000 a 49.6 46.1 43.8 
Black race 7.7 7.9 8.0 
Number of morbidities     
0-3 73.3 73.3 72.4 
≥4 26.7 26.7 27.6 
Self-reported health status    
Excellent, very good, 
or good 78.7 81.0 80.7 
Fair or poor 21.3 19.0 19.3 
Prescription drug coverage b    
Part D: Low-Income 
Subsidy 13.9 13.2 14.0 
Part D: Medicare 
advantage plan 17.1 20.0 21.2 
Part D: Stand-alone 
drug plan 22.8 23.2 24.2 
Non-Part D coverage  42.9 40.0 37.1 
None 3.3 3.4 3.5 
Source: Authors’ analysis.  
Notes: 
a MCBS variable, not adjusted for inflation. 
b Estimated using a combination of self-reported and CMS administrative 
data, available in the MCBS ATC.  Presented hierarchically, such that 
beneficiaries with a mix of coverage types are counted in the category 
appearing first.  “Non-Part D coverage” includes employer-sponsored drug 
coverage for current or retired workers, Tricare for veterans, self-
purchased plans, and other public and private coverage sources; non-Part D 
sources above may not all qualify as “creditable”. (Reference: Centers for 
Medicare and Medicaid Services (CMS). What is creditable coverage? 2006; 
http://www.cms.gov/Medicare/Prescription-Drug-
Coverage/CreditableCoverage/Downloads/whatiscreditablecoverage.pdf. 
Accessed March 13, 2013.)  
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Exhibit 4 – Changes in CRN (A) and spending less on basic needs (B) 
among overall and sub-groups of community-dwelling Medicare 
beneficiaries (See Supplemental Appendix Exhibit 1 for details). 
(A) Cost-related medication nonadherence 
Adjusted OR (95% CI) a 
     
  Period 1 Period 2 Overall 
Period 
Group No. b   2009 vs. 2007 2011 vs. 2009 2011 vs. 2007 
Elderly 69,697 0.90 1.05 0.95 
No. of 
morbidities      
0-3 49,650 0.86 0.97 0.83* 
≥4 20,047 0.98 1.20* 1.18* 
Income, US$     
<25,000 34,776 0.94 0.99 0.94  
≥25,000 34,889 0.84 1.12 0.95 
 
(B) Spending less on basic needs 
 
Elderly 69,656 0.71** 1.34** 0.96 
No. of 
morbidities     
0-3 49,629 0.65** 1.18 0.77* 
≥4 20,027 0.81* 1.54** 1.25* 
Income, US$     
<25,000 34,748 0.78** 1.25* 0.98 
≥25,000 34,876 0.57** 1.60** 0.90 
Source: Authors’ analysis.  
Notes:  
a  Adjusted for younger age, female sex, non-white race, income <$25,000, 
poor health, survey participation, and having 4 or more morbidities. 
b Numbers of person-years in subgroups do not necessarily add up to overall 
number of observations. Numbers vary with response rates and availability 
of data on subgroups.  
* P<0.05 
** P<0.001 
 
